Bibliographic Details
| Title: |
Front-Line Bevacizumab plus Chemotherapy with or without Maintenance Therapy for Metastatic Breast Cancer: An Observational Study by the Hellenic Oncology Research Group. |
| Authors: |
Kokkali, Stefania, Saloustros, Emmanouil, Stefanou, Dimitra, Makrantonakis, Paris, Kentepozidis, Nikolaos, Boukovinas, Ioannis, Xenidis, Nikolaos, Katsaounis, Panagiotis, Ardavanis, Alexandros, Ziras, Nikolaos, Christopoulou, Athina, Rigas, George, Kalbakis, Kostas, Vardakis, Nikolaos, Emmanouilides, Christos, Athanasiadis, Ilias, Anagnostopoulos, Athanassios, Hatzidaki, Dora, Prinarakis, Efthimios, Simopoulou, Foteini |
| Source: |
Current Oncology; Feb2022, Vol. 29 Issue 2, p1237-1251, 15p, 6 Charts, 4 Graphs |
| Subject Terms: |
BREAST cancer prognosis, FATIGUE risk factors, SCIENTIFIC observation, ACQUISITION of data methodology, CONFIDENCE intervals, CANCER chemotherapy, EPIDERMAL growth factor, METASTASIS, ANTINEOPLASTIC agents, RETROSPECTIVE studies, NEUTROPENIA, SURVIVAL analysis (Biometry), MEDICAL records, ANEMIA, DESCRIPTIVE statistics, BEVACIZUMAB, TERMINATION of treatment, BREAST tumors, DISEASE risk factors |
| Abstract: |
Front-line bevacizumab (BEV) in combination with taxanes offers benefit in progression-free survival (PFS) in metastatic breast cancer (mBC). The medical records of mBC patients, treated with front-line BEV-based chemotherapy, were retrospectively reviewed in order to generate real life safety and efficacy data. Patients with human epidermal growth factor receptor 2 (HER2)-negative mBC treated with front-line BEV in combination with chemotherapy were eligible. Maintenance therapy with BEV and/or hormonal agents was at the physicians' discretion. Among the 387 included patients, the most common adverse events were anemia (61.9%, mainly grade 1), grade 3/4 neutropenia (16.5%), grade 1/2 fatigue (22.3%), and grade 1/2 neuropathy (19.6%). Dose reductions were required in 164 cycles (7.1%) and toxicity led to treatment discontinuation in 21 patients (5.4%). The median PFS and the median overall survival (OS) were 13.3 (95% CI: 11.7–14.8) and 32.3 months (95% CI: 27.7–36.9), respectively. Maintenance therapy, with hormonal agents (ET) and/or BEV, was associated with longer OS versus no maintenance therapy (47.2 versus 23.6 months; p < 0.001) in patients with hormone receptor (HR)-positive disease and BEV maintenance offered longer OS versus no maintenance in patients with HR-negative disease (52.8 versus 23.3; p = 0.023). These real-life data show that front-line BEV-based chemotherapy in HER2-negative mBC patients is an effective treatment with an acceptable toxicity profile. The potential benefit of maintenance treatment, especially ET, is important and warrants further research. [ABSTRACT FROM AUTHOR] |
|
Copyright of Current Oncology is the property of MDPI and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.) |
| Database: |
Complementary Index |
|
Full text is not displayed to guests. |
Login for full access.
|
